This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

The company will no longer cover Zepbound, which is made by Eli Lilly, which was approved in November 2023 by the Food and Drug Administration for weight management in adults who are obese or are ...

CNBC's Angelica Peebles reports on news regarding CVS. Qantas hit by cyberattack, six million customers' data potentially ...

CVS’ deal with Novo Nordisk is a major shakeup in the lucrative market for obesity drugs — and a blow to rival drugmaker Eli Lilly, which also manufactures GLP-1 medications like Zepbound. On July 1, ...

CVS opts for Wegovy over Zepbound, affecting drug access for some. CVS Health also said Thursday that it will start selling Wegovy at a discounted price of about $500 monthly at thousands of ...

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.